Finance

Ubl

Pharma

Drug industry’s big trade group breaks its record for lobbying spending in a quarter

By Rebecca Robbins and Erin Mershon

Akili screenshot

Business

A digital medicine company tries to adopt pharma’s patent game. Will it work?

By Rebecca Robbins

advertisement

CORY BOOKER

Pharmalot

Senator lashes out at drug makers for stock buybacks, but not cutting prices

By Ed Silverman

advertisement

Alexion Pharmaceuticals Inc

Business

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

By Adam Feuerstein

STAT Plus panel

Biotech

Why are some of New York’s top investors bullish on biotech? The science is getting better

By Adam Feuerstein

Pharmalot

Pharmalittle: Celgene No. 2 exec leaves abruptly; Walmart looks at buying PillPack

By Ed Silverman

Pharmalot

Pharmalittle: Can Takeda afford to buy Shire? Alkermes depression drug hits an FDA roadblock

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: CVS exec tapped to run White House drug-pricing reform; Walmart in talks to buy Humana

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Takeda may bid for Shire; a Medicare rule on opioids causes blowback

By Ed Silverman

Pharmalot

Pharmalittle: Glaxo drops out of bidding for Pfizer consumer unit; Trump policy could hike prices for biosimilars

By Ed Silverman

Pharmalot

AbbVie lung cancer results are raising questions about a $6 billion deal

By Ed Silverman

Business

A doctor speaks, a biotech stock tanks. What happened at this invite-only health care investor conference?

By Adam Feuerstein

HOLMES & Balwani HP

Business

Investigators say his fingerprints are all over financial crimes at Theranos. Why is he a virtual ghost?

By Rebecca Robbins, Damian Garde, and Adam Feuerstein

Hepatitis Drugs

Business

End of an era: Gilead’s longtime R&D chief is stepping down at a pivotal moment for the company

By Rebecca Robbins

Biotech

Investors are pouring money into consumer genomics. Will their bets pay off?

By Rebecca Robbins

Stethoscope on white background

First Opinion

The steady growth in health care jobs isn’t all positive

By Nisarg A. Patel

Adam's Take

Omeros cataract surgery drug sales vanished and now a loan default is a real risk

By Adam Feuerstein

Chest thumping

Adam's Take

Biotech is full of chest-thumping press releases. This one thumps really hard

By Adam Feuerstein and Damian Garde

Speaking

First Opinion

I have brain cancer. Drug companies and med schools should be compensating me for my expertise

By Adam Hayden

Alex Brandon/AP

Pharmalot

A new FTC policy may alter the calculus for some pharma M&A deals

By Ed Silverman

Pharmalot

Drug makers loathe these patent challenges, and more are being filed than ever before

By Ed Silverman

Pharmalot

Pharmalittle: Walgreens eyes AmerisourceBergen for a takeover; FDA OKs a new Vertex CF treatment

By Ed Silverman

Benjamins

Biotech

Investors are making bigger first-time bets — not more bets — on life sciences companies

By Rebecca Robbins

Moderna

Biotech

Biotech’s biggest unicorn is now worth $7.5 billion

By Damian Garde

Pharmalot

The Ablynx deal is another big bet by Sanofi to remake itself

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi wins bidding for Ablynx; Roche hemophilia drug can reduce costs

By Ed Silverman

Biotech column IMAGE

Biotech

Everything’s coming up biotech — and that has some investors spooked

By Damian Garde

Michel Vounatsos

Biotech

Biogen earnings lack blockbuster acquisition pop, but executives pledge to keep looking

By Adam Feuerstein

Adam's Take

The biotech M&A spotlight shifts to Biogen, with some clear candidates to acquire

By Adam Feuerstein